ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1746

Immune Complex-Induced IL-6 Production By Lupus Prone Mesangial Cells Is Mediated By Neuraminidase Activity

Tamara K. Nowling1, Kamala Sundararaj2 and Leah Siskind3, 1Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, 2Medicine, Medical University of South Carolina, Charleston, SC, 3Pharmacology and Toxicology, University of Louisville, Louisville, KY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cell Signaling, lipids and lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Animal Models - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We made the novel observation that glycosphingolipid (GSL) levels and neuraminidase (NEU) (an enzyme that mediates GSL catabolism) activity/expression are altered in the kidneys and/or urine of lupus mice and human patients with proliferative nephritis compared to their non-nephritic counterparts and healthy controls. Specifically, elevated GSL levels were observed in the mesangial region of glomeruli. We hypothesize that activation of mesangial cells (MCs) in the progression of lupus nephritis is mediated in part by NEU1-mediated LacCer elevation, contributing to renal inflammation in lupus nephritis.

Methods: NEU1 expression and the GSL Lactosylceramide (LacCer) levels in kidney sections were analyzed by immunohistochemistry and immunofluorescence. MES13 mouse MCs were: 1) incubated with the GSLs LacCer and glucosylceramide (GlcCer) over time and cytokine gene expression measured by real-time RTPCR; and 2) transfected with increasing amounts of an expression vector for NEU1, and IL-6 production was measured in the media by ELISA, while cellular LacCer levels were measured by Supercritical Fluid Chromatography coupled with tandem mass spectrometry. Primary MCs were grown from glomeruli isolated from kidneys of pre-nephritic MRL/lpr mice. Once established and verified to be MCs, the primary MCs were analyzed between passages 6 and 10 following activation with heat aggregated IgG (HA-IgG, a mimic of immune complex deposition) for IL-6 and MCP-1 production by ELISA, Neu1 message levels by real-time RTPCR, and NEU1 expression and cellular localization by immunofluorescence.

Results: NEU1 and LacCer were observed to be highly expressed in MCs on renal sections of nephritic MRL/lpr mice by immunohistochemistry. Using the mouse MES13 MC line, we demonstrate that exogenous addition of LacCer and GlcCer increases the expression of several cytokines, including IL-6. Over-expression of NEU1 increases LacCer levels and IL-6 production. In primary MCs from pre-nephritic lupus mice, Neu1 expression, IL-6 production and MCP-1 production are significantly increased following addition of HA-IgG in a dose-dependent manner. IL-6 production is significantly increased within 6 hours following addition of HA-IgG stimulation. Importantly, addition of an FDA-approved inhibitor of NEU activity significantly and dose-dependently inhibited HA-IgG-induced IL-6, but not MCP-1 production. NEU1, typically located in the lysosomes, is translocated to the plasma membrane in some cell types upon activation. Analyses of changes in cellular localiation of NEU1 in HA-IgG-activated lupus prone MCs is pending.

Conclusion: Together these results suggest that immune complex activated IL-6 production of MRL/lpr lupus prone MCs is mediated by NEU-mediated GSL catabolism. Targeting NEU activity, or NEU1 specifically, may reduce MC cytokine production and thus renal inflammation in lupus nephritis.


Disclosure: T. K. Nowling, None; K. Sundararaj, None; L. Siskind, None.

To cite this abstract in AMA style:

Nowling TK, Sundararaj K, Siskind L. Immune Complex-Induced IL-6 Production By Lupus Prone Mesangial Cells Is Mediated By Neuraminidase Activity [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/immune-complex-induced-il-6-production-by-lupus-prone-mesangial-cells-is-mediated-by-neuraminidase-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-complex-induced-il-6-production-by-lupus-prone-mesangial-cells-is-mediated-by-neuraminidase-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology